Ehret, Felix ORCID: 0000-0001-6177-1755, Kufeld, Markus, Fuerweger, Christoph, Haidenberger, Alfred, Fichte, Susanne, Lehrke, Ralph, Senger, Carolin, Kaul, David, Bleif, Martin, Becker, Gerd, Ruess, Daniel, Ruge, Maximilian, Schichor, Christian, Tonn, Joerg-Christian and Muacevic, Alexander (2022). The Role of Stereotactic Radiosurgery in the Management of Foramen Magnum Meningiomas-A Multicenter Analysis and Review of the Literature. Cancers, 14 (2). BASEL: MDPI. ISSN 2072-6694

Full text not available from this repository.

Abstract

Simple Summary Meningiomas represent the most common central nervous system (CNS) tumor. Despite their often benign nature, a tumor location in direct proximity to vital brain structures may lead to significant morbidity. This is the case for foramen magnum meningiomas (FMMs) as they grow at the skull base, next to the brain stem and foramen magnum. Surgical resection represents the mainstay of FMM treatments. In patients unsuitable for surgery, with tumor recurrences or tumor remnants after surgery, non-invasive treatment modalities may play a crucial role in patient management. Reports and studies on stereotactic radiosurgery (SRS) for the treatment of FMMs are scarce. This multicenter analysis reported the outcome data of 62 patients with FMMs. SRS achieved a high local tumor control and demonstrated a favorable safety profile. These results are in agreement with previous findings. SRS should be considered for selected FMM patients. Background: Foramen magnum meningiomas (FMMs) represent a considerable neurosurgical challenge given their location and potential morbidity. Stereotactic radiosurgery (SRS) is an established non-invasive treatment modality for various benign and malignant brain tumors. However, reports on single-session or multisession SRS for the management and treatment of FMMs are exceedingly rare. We report the largest FMM SRS series to date and describe our multicenter treatment experience utilizing robotic radiosurgery. Methods: Patients who underwent SRS between 2005 and 2020 as a treatment for a FMM at six different centers were eligible for analysis. Results: Sixty-two patients met the inclusion criteria. The median follow-up was 28.9 months. The median prescription dose and isodose line were 14 Gy and 70%, respectively. Single-session SRS accounted for 81% of treatments. The remaining patients received three to five fractions, with doses ranging from 19.5 to 25 Gy. Ten (16%) patients were treated for a tumor recurrence after surgery, and thirteen (21%) underwent adjuvant treatment. The remaining 39 FMMs (63%) received SRS as their primary treatment. For patients with an upfront surgical resection, histopathological examination revealed 22 World Health Organization grade I tumors and one grade II FMM. The median tumor volume was 2.6 cubic centimeters. No local failures were observed throughout the available follow-up, including patients with a follow-up >= five years (16 patients), leading to an overall local control of 100%. Tumor volume significantly decreased after treatment, with a median volume reduction of 21% at the last available follow-up (p < 0.01). The one-, three-, and five-year progression-free survival were 100%, 96.6%, and 93.0%, respectively. Most patients showed stable (47%) or improved (21%) neurological deficits at the last follow-up. No high-grade adverse events were observed. Conclusions: SRS is an effective and safe treatment modality for FMMs. Despite the paucity of available data and previous reports, SRS should be considered for selected patients, especially those with subtotal tumor resections, recurrences, and patients not suitable for surgery.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Ehret, FelixUNSPECIFIEDorcid.org/0000-0001-6177-1755UNSPECIFIED
Kufeld, MarkusUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fuerweger, ChristophUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Haidenberger, AlfredUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fichte, SusanneUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lehrke, RalphUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Senger, CarolinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kaul, DavidUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bleif, MartinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Becker, GerdUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ruess, DanielUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ruge, MaximilianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schichor, ChristianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Tonn, Joerg-ChristianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Muacevic, AlexanderUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-690408
DOI: 10.3390/cancers14020341
Journal or Publication Title: Cancers
Volume: 14
Number: 2
Date: 2022
Publisher: MDPI
Place of Publication: BASEL
ISSN: 2072-6694
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
GAMMA-KNIFE RADIOSURGERY; METHYLATION-BASED CLASSIFICATION; RADIATION-THERAPY; POSTERIOR-FOSSA; SYSTEM; BRAINMultiple languages
OncologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/69040

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item